

84-50, Nevskiy Prospekt
St. Petersburg, Russia, 191025
Telephone: +7812-3151522
Fax: +7812-3151522
e-mail: office@itpcru.org
www.itpcru.org



Коалиция по
ГОТОВНОСТИ К
ЛЕЧЕНИЮ

Сетевое издание
Н/с Эл № ФС77 - 54304

191025, Санкт-Петербург
Невский проспект, 84-50
Телефон: +7812-3151522
Факс: +7812-3151522
e-mail: office@itpcru.org
www.itpcru.org

To:
Gilead Sciences Inc.
333 Lakeside Drive, Foster City, California 94404, USA
John F. Milligan,
PhD, President and Chief Executive Officer
CC: Gregg H. Alton
Executive Vice President
Commercial and Access Operations ALA, Corporate and Medical Affairs
Gregg.Alton@gilead.com
CC: Igor Rukavishnikov
Head of Gilead Sciences, Russia
igor.rukavishnikov@gilead.com

Open Letter to Gilead Sciences

With this letter, Treatment Preparedness Coalition would like to voice its concern regarding the absence of sofosbuvir on the Russian market. The drug was registered in Russia in March 2016; however, since the registration date there have been no supplies of sofosbuvir based on the results of the government procurement and commercial market monitoring.

Treatment Preparedness Coalition is continuously analyzing the procurement of drugs for treating HIV and HCV in Russia and other countries. Over the course of the monitoring in 2016, we identified a number of auctions for sofosbuvir; however, in almost all of the cases there were no bids. Below are some examples of such auctions:

1. Moscow: <http://zakupki.gov.ru/epz/order/notice/ea44/view/common-info.html?regNumber=0873200009816001592>
2. Moscow: <http://zakupki.gov.ru/epz/order/notice/ea44/view/common-info.html?regNumber=0873200009816001483>
3. St. Petersburg: <http://zakupki.gov.ru/epz/order/notice/ea44/view/common-info.html?regNumber=0372200168116000193>
4. Bashkortostan: <http://zakupki.gov.ru/epz/order/notice/ea44/view/common-info.html?regNumber=0301200034616000022>

We would like to stress once again that **access to sofosbuvir-based regimens at affordable prices is essential for an effective HCV response** according to the current recommendations by WHO and the leading associations for the study of the liver diseases. We would be very grateful if you could inform us about the tentative dates of the supply of sofosbuvir to the Russian market and the price for sofosbuvir. The prices cited in the

auctions are around USD10,000 per 12 weeks of treatment, which is approximately 30 times higher than the prices currently offered by the Indian generics under the Gilead license. In this regard, we would like to ask you once again **to include Russia in the list of countries covered by the license for sofosbuvir, ledipasvir and velpatasvir concluded between Gilead and Indian generic producers¹** or to take measure to ensure access to sofosbbuvir-based regimens in Russia at prices close to the prices offered by generic companies under the afore-mentioned license.

Sincerely,

Gregory Vergus, Regional Coordinator



October 12, 2016

¹<http://gilead.com/~media/files/pdfs/other/hcv%20generic%20agreement%20fast%20facts%20062816.pdf>